Literature DB >> 27377046

Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator.

Gregory Thiabaud1, Rebecca McCall2, Guangan He3, Jonathan F Arambula2, Zahid H Siddik4, Jonathan L Sessler5.   

Abstract

Water-soluble platinum(IV) prodrugs, which proved kinetically stable to reduction in the presence of physiological concentration of ascorbate, were quickly reduced to their active form, oxaliplatin, when co-incubated with a macrocycle metallotexaphyrin (i.e., Motexafin Gadolinium (MGd)). The reduction of Pt(IV) to Pt(II) promoted by MGd occurs in cell culture as well, leading to an increase in the antiproliferative activity of the Pt(IV) species in question. The mediated effect is proportional to the concentration of MGd and gives rise to an enhancement when the prodrug is relatively hydrophilic. MGd is known to localize/accumulate preferentially in tumor tissues. Thus, the present "activation by reduction" approach may allow for the cancer-selective enhancement in the cytotoxicity of Pt(IV) prodrugs.
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  antitumor agents; metallotexaphyrin; platinum; prodrugs; redox chemistry

Mesh:

Substances:

Year:  2016        PMID: 27377046      PMCID: PMC5039070          DOI: 10.1002/anie.201604236

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   15.336


  25 in total

Review 1.  Exploiting tumour hypoxia in cancer treatment.

Authors:  J Martin Brown; William R Wilson
Journal:  Nat Rev Cancer       Date:  2004-06       Impact factor: 60.716

2.  In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer.

Authors:  R A Miller; K Woodburn; Q Fan; M F Renschler; J L Sessler; J A Koutcher
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-11-01       Impact factor: 7.038

Review 3.  The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.

Authors:  Timothy C Johnstone; Kogularamanan Suntharalingam; Stephen J Lippard
Journal:  Chem Rev       Date:  2016-02-11       Impact factor: 60.622

Review 4.  Cellular pathways for transport and efflux of ascorbate and dehydroascorbate.

Authors:  Alessandro Corti; Alessandro F Casini; Alfonso Pompella
Journal:  Arch Biochem Biophys       Date:  2010-05-28       Impact factor: 4.013

5.  Late first-row transition-metal complexes of texaphyrin.

Authors:  Sharon Hannah; Vincent Lynch; Dirk M Guldi; Nikolay Gerasimchuk; Charles L B MacDonald; Darren Magda; Jonathan L Sessler
Journal:  J Am Chem Soc       Date:  2002-07-17       Impact factor: 15.419

6.  Photoinduced reduction of Pt(IV) within an anti-proliferative Pt(IV)-texaphyrin conjugate.

Authors:  Grégory Thiabaud; Jonathan F Arambula; Zahid H Siddik; Jonathan L Sessler
Journal:  Chemistry       Date:  2014-06-24       Impact factor: 5.236

7.  Synthesis and anticancer properties of water-soluble zinc ionophores.

Authors:  Darren Magda; Philip Lecane; Zhong Wang; Weilin Hu; Patricia Thiemann; Xuan Ma; Patricia K Dranchak; Xiaoming Wang; Vincent Lynch; Wenhao Wei; Viktor Csokai; Joseph G Hacia; Jonathan L Sessler
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

8.  Motexafin gadolinium reacts with ascorbate to produce reactive oxygen species.

Authors:  Darren Magda; Nikolay Gerasimchuk; Philip Lecane; Richard A Miller; John E Biaglow; Jonathan L Sessler
Journal:  Chem Commun (Camb)       Date:  2002-11-21       Impact factor: 6.222

Review 9.  The controversial place of vitamin C in cancer treatment.

Authors:  J Verrax; P Buc Calderon
Journal:  Biochem Pharmacol       Date:  2008-09-30       Impact factor: 5.858

10.  A Photoactivatable Platinum(IV) Complex Targeting Genomic DNA and Histone Deacetylases.

Authors:  Jana Kasparkova; Hana Kostrhunova; Olga Novakova; Radka Křikavová; Ján Vančo; Zdeněk Trávníček; Viktor Brabec
Journal:  Angew Chem Int Ed Engl       Date:  2015-10-12       Impact factor: 15.336

View more
  7 in total

1.  Porphyrinoid Drug Conjugates.

Authors:  Jonathan F Arambula; Jonathan L Sessler
Journal:  Chem       Date:  2020-07-09       Impact factor: 22.804

2.  Oxaliplatin Pt(IV) prodrugs conjugated to gadolinium-texaphyrin as potential antitumor agents.

Authors:  Grégory Thiabaud; Guangan He; Sajal Sen; Kathryn A Shelton; Wallace B Baze; Luke Segura; Julie Alaniz; Ruben Munoz Macias; Greg Lyness; Alan B Watts; Hyun Min Kim; Hyunseung Lee; Mi Young Cho; Kwan Soo Hong; Rick Finch; Zahid H Siddik; Jonathan F Arambula; Jonathan L Sessler
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-16       Impact factor: 11.205

3.  Riboflavin as a bioorthogonal photocatalyst for the activation of a PtIV prodrug.

Authors:  Silvia Alonso-de Castro; Emmanuel Ruggiero; Ane Ruiz-de-Angulo; Elixabete Rezabal; Juan C Mareque-Rivas; Xabier Lopez; Fernando López-Gallego; Luca Salassa
Journal:  Chem Sci       Date:  2017-04-19       Impact factor: 9.825

4.  NF-κB hijacking theranostic Pt(ll) complex in cancer therapy.

Authors:  Yingzhong Zhu; Mingzhu Zhang; Lei Luo; Martin R Gill; Cesare De Pace; Giuseppe Battaglia; Qiong Zhang; Hongping Zhou; Jieying Wu; Yupeng Tian; Xiaohe Tian
Journal:  Theranostics       Date:  2019-04-12       Impact factor: 11.556

Review 5.  The Potential of Lonidamine in Combination with Chemotherapy and Physical Therapy in Cancer Treatment.

Authors:  Yaxin Huang; Guohui Sun; Xiaodong Sun; Feifan Li; Lijiao Zhao; Rugang Zhong; Yongzhen Peng
Journal:  Cancers (Basel)       Date:  2020-11-11       Impact factor: 6.639

6.  Gd(iii)-Pt(iv) theranostic contrast agents for tandem MR imaging and chemotherapy.

Authors:  Casey J Adams; Thomas J Meade
Journal:  Chem Sci       Date:  2020-01-28       Impact factor: 9.825

7.  Towards Imaging Pt Chemoresistance Using Gd(III)-Pt(II) Theranostic MR Contrast Agents.

Authors:  Casey J Adams; Thomas J Meade
Journal:  ChemMedChem       Date:  2021-08-06       Impact factor: 3.466

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.